ASTROGEN

Company History

With years of clinical experience, Astrogen is exploring new horizons
in medications development field at an unprecedented speed.

2023

2022

SeptemberSigned an MOU with the Dept. of Neurosurgery
of Seoul National University Bundang Hospital
Signed an MOU with the Molecular Biology &
Phylogeny Lab. (MPL) of the Dept. of Biological
Sciences of Pusan National University
AugustSelected as Employment-Friendly Company by Daegu City
Selected as one of BIG3 projects by the Ministry
of SMEs and Startups
Designated as Startup Growth Technology
Development Project
Received the investment of Bridge 2 (KRW 3 billion)
JuneSigned an MOU with the Value Development
and Play Center
MayCompleted observation for the final subject of
the phase 2 clinical trial for AST-001
FebruaryReceived the investment of Bridge 1 (KRW 9 billion)

2021

DecemberReceived Presidential Citation for Venture
Startup Promotion Merit Award
Certified as Family-Friendly Company by
the Ministry of Gender Equality & Family
Collaborated with IKTOS, AI-based
new drug development company
NovemberDesignated as Excellent Corporate R&D Center
by the Ministry of Science and ICT
OctoberIntroduced Astrogen’s ESG ethical management
SeptemberUploaded the Astrogen ESG Report on the website
Selected as Pre-Star Company by Daegu City
FebruaryPhase 1 Clinical Study Report for AST-001 (CSR)
Enrolled the first trial subject in the phase
2 clinical trial for AST-001

2020

DecemberReceived the investment of Series B (KRW 13 billion)
Received Grand Prize at the Daegu Startup Awards
by the Daegu Center for Creative Economy Innovation
Received Minister Award from the Ministry of Trade,
Industry and Energy for revitalizing free economic zone
NovemberSelected as the National Representative Innovative
Company by the Financial Services Commission
AugustOpened the Astrogen's Pharmaceutical Research
Institute (Naju) Office
JulyReceived approval of IND application for phase 2
clinical trial for AST-001
JuneSelected as “Baby Unicorn” company by the Ministry
of SMEs and Startups
MayCompleted construction of Astrogen’s new office building
MarchReceived IND for phase 1 clinical trial for AST-001

2019

DecemberStarted construction of Astrogen’s new building
and research center
NovemberSelected as the Frontier Venture Company by
the Korea Technology Finance Corp. (KIBO)
Selected as A+ Member by the KIBO
AugustReceived the investment of Series A
(KRW 5 billion of capital increase)
MayObtained the approval to move into
the Daegu-Gyeongbuk Medical Cluster
MarchOpened the Astrogen's Business Development
Division (Seoul) office

2018

2017